secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0000950170-23-002893
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences nominates first herpesvirus candidate ABI-5366, a long-acting HSV-2 helicase inhibitor
--------------------------------------------------------------------------------

- ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.
- Preclinical data show nanomolar potency in vitro and exceptionally low clearance, supporting at least monthly dosing.
- Company plans to file IND/CTA in first half of 2024; more data expected at scientific conferences in 2023.
- First development candidate from Assembly Bio's expanded focus beyond hepatitis B.
- Current therapies for high-recurrence genital herpes are only partially effective; helicase inhibitors previously showed greater reductions in shedding and lesions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/0000950170-23-002893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/asmb-20230215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer